It is estimated that approximately 154000 women in the United States have stage IV breast cancer (BC). A subset of this group has metastatic disease at presentation, known as de novo stage IV disease. De novo stage IV BC accounts for approximately 6% of all BC diagnoses in the United States. Traditionally, stage IV BC patients are treated with primary systemic therapy with a palliative intent reserving possible locoregional treatment (LRT) as last resort. There has been a lot of interest in the role of LRT in de novo stage IV BC for the past decade with mixed conclusions. Although this review is not intended to be a comprehensive overview of all literature regarding this topic to date, we will review the recent findings in literature focusing on the studies with larger sample sizes to investigate the role of LRT in de novo stage IV BC.

据估计，在美国大约有154000名妇女患有IV期乳腺癌（BC）。该组中的一部分在出现时具有转移性疾病，即从头开始的IV期疾病。从头开始的IV期BC约占美国所有BC诊断的6％。传统上，对IV期BC患者采用主要的全身治疗，以姑息性治疗为最终目的，保留可能的局部治疗（LRT）。在过去的十年中，人们对轻快铁在从头开始的第四阶段BC的作用引起了很多兴趣，但结论不一。尽管本综述并非旨在到目前为止就该主题的所有文献进行全面概述，但我们将回顾文献中的最新发现，重点关注具有较大样本量的研究，以研究LRT在BC新阶段IV中的作用。